Whilst it may not be a huge deal, we thought it was good to see that the AngioDynamics, Inc. (NASDAQ:ANGO) CEO, President & Director, James Clemmer, recently bought US$67k worth of stock, for US$6.70 per share.    Although the purchase is not a big one, increasing their shareholding by only 2.6%, it can be interpreted as a good sign.    

The Last 12 Months Of Insider Transactions At AngioDynamics

In fact, the recent purchase by James Clemmer was the biggest purchase of AngioDynamics shares made by an insider individual in the last twelve months, according to our records.     So it's clear an insider wanted to buy, at around the current price, which is US$6.80.  Of course they may have changed their mind. But this suggests they are optimistic.  We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price.   In this case we're pleased to report that the insider bought shares at close to current prices.  James Clemmer was the only individual insider to buy during the last year.    

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.  If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGS:ANGO Insider Trading Volume April 12th 2024

AngioDynamics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.  I reckon it's a good sign if insiders own a significant number of shares in the company.   Insiders own 2.9% of AngioDynamics shares, worth about US$7.9m, according to our data.  We do generally prefer see higher levels of insider ownership.  

So What Do The AngioDynamics Insider Transactions Indicate?

It is good to see the recent insider purchase.    And the longer term insider transactions also give us confidence.   But we don't feel the same about the fact the company is making losses.    While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that AngioDynamics insiders are reasonably well aligned, and optimistic for the future.      So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company.    At Simply Wall St, we found 2 warning signs for AngioDynamics that deserve your attention before buying any shares.  

Of course AngioDynamics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.